Developments towards effective treatments for Nipah and Hendra virus infection

References

• Lamb RA, Kolakofsky D. Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 1305–1340 (2001).
   Google Scholar
• Murray K, Eaton B, Hooper P et al. Emerging Infections. Scheld WM, Armstrong D, Hughes JM (Eds). ASM Press, Washington, DC, USA, 43–58 (1998).
   Google Scholar
• Chua KB. Nipah virus outbreak in Malaysia. J. Clin. Virol. 26, 265–275 (2003).
   PubMed Web of Science ®Google Scholar
• Selvey LA, Wells RM, McCormack JG et al. Infection of humans and horses by a newly described morbillivirus. Med. J. Aust. 162, 642–645 (1995).
   PubMed Web of Science ®Google Scholar
• Wong KT, Shieh WJ, Kumar S et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am. J. Pathol. 161, 2153–2167 (2002).
   PubMed Web of Science ®Google Scholar
• Tan CT, Wong KT. Nipah encephalitis outbreak in Malaysia. Ann. Acad. Med. Singapore 32, 112–117 (2003).
   PubMed Web of Science ®Google Scholar
• Halpin K, Young PL, Field HE, Mackenzie JS. Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus. J. Gen. Virol. 81, 1927–1932 (2000).
   PubMed Web of Science ®Google Scholar
• Chua KB, Lek Koh C, Hooi PS et al. Isolation of Nipah virus from Malaysian island flying-foxes. Microbes Infect. 4, 145–151 (2002).
   PubMed Web of Science ®Google Scholar
• Anonymous. Pro-med. International Society for Infectious Diseases (2004).
   Google Scholar
• Anonymous. Emerging infections update: November 2004 to January 2005. Commun. Dis. Rep. Wkly 15 (2005).
   Google Scholar
• Anonymous. Nipah encephalitis outbreak over wide area of western Bangladesh, 2004. Health and Science Bulletin (ICDDR,B) 2, 7–11 (2004).
   Google Scholar
• Hsu VP, Hossain MJ, Parashar UD et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg. Infect. Dis. 10, 2082–2087 (2004).
   PubMed Web of Science ®Google Scholar
• Anonymous. Person-to-person transmission of Nipah virus during outbreak in Faridpur District, 2004. Health and Science Bulletin (ICDDR,B) 2, 5–9 (2004).
   Google Scholar
• Hooper P, Zaki S, Daniels P, Middleton D. Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect. 3, 315–322 (2001).
   PubMed Web of Science ®Google Scholar
• Lam SK, Chua KB. Nipah virus encephalitis outbreak in Malaysia. Clin. Infect. Dis. 34, S48–S51 (2002).
   Google Scholar
• Bonaparte MI, Dimitrov AS, Bossart KN et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc. Natl Acad. Sci. USA 102, 10652–10657 (2005).
   PubMed Web of Science ®Google Scholar
• Negrete OA, Levroney EL, Aguilar HC et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436, 401–405 (2005).
   PubMed Web of Science ®Google Scholar
• Poliakov A, Cotrina M, Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell 7, 465–480 (2004).
   PubMedGoogle Scholar
• Drescher U. Eph family functions from an evolutionary perspective. Curr. Opin. Genet. Dev. 12, 397–402 (2002).
   PubMedGoogle Scholar
• Flanagan JG, Vanderhaeghen P. The ephrins and Eph receptors in neural development. Ann. Rev. Neurosci. 21, 309–345 (1998).
   PubMed Web of Science ®Google Scholar
• Adams RH, Wilkinson GA, Weiss C et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 13, 295–306 (1999).
   PubMed Web of Science ®Google Scholar
• Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741–753 (1998).
   PubMed Web of Science ®Google Scholar
• Yob JM, Field H, Rashdi AM et al. Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. Emerg. Infect. Dis. 7, 439–441 (2001).
   PubMed Web of Science ®Google Scholar
• Middleton DJ, Westbury HA, Morrissy CJ et al. Experimental Nipah virus infection in pigs and cats. J. Comp. Pathol. 126, 124–136 (2002).
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub S, Copps J et al. Invasion of the central nervous system in a porcine host by Nipah virus. J. Virol. 79, 7528–7534 (2005).
   PubMed Web of Science ®Google Scholar
• Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect. 3, 289–295 (2001).
   PubMed Web of Science ®Google Scholar
• Westbury HA, Hooper PT, Selleck PW, Murray PK. Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus. Aust. Vet. J. 72, 278–279 (1995).
   PubMed Web of Science ®Google Scholar
• Hooper PT, Westbury HA, Russell GM. The lesions of experimental equine morbillivirus disease in cats and guinea-pigs. Vet. Pathol. 34, 323–329 (1997).
   PubMedGoogle Scholar
• Williamson MM, Hooper PT, Selleck PW, Westbury HA, Slocombe RF. A guinea-pig model of Hendra virus encephalitis. J. Comp. Pathol. 124, 273–279 (2001).
   PubMed Web of Science ®Google Scholar
• Wong KT, Grosjean I, Brisson C et al. A golden hamster model for human acute Nipah virus infection. Am. J. Pathol. 163, 2127–2137 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper PT, Ketterer PJ, Hyatt AD, Russell GM. Lesions of experimental equine morbillivirus pneumonia in horses. Vet. Pathol. 34, 312–322 (1997).
   PubMed Web of Science ®Google Scholar
• Westbury HA, Hooper PT, Brouwer SL, Selleck PW. Susceptibility of cats to equine morbillivirus. Aust. Vet. J. 74, 132–134 (1996).
   PubMed Web of Science ®Google Scholar
• Williamson MM, Hooper PT, Selleck PW et al. Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats. Aust. Vet. J. 76, 813–818 (1998).
   PubMed Web of Science ®Google Scholar
• Morrison TG. The three faces of paramyxovirus attachment proteins. Trends Microbiol. 9, 103–105 (2001).
   PubMedGoogle Scholar
• Murphy BR, Chanock RM. Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 435–468 (2001).
   Google Scholar
• Quinnan GV. Antiviral Agents and Human Viral Disease. Galasso G, Whitley R, Merigan TC (Eds). Raven Press, NY, USA, 791–834 (1997).
   Google Scholar
• Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat. Med. 10, 806–810 (2004).
   PubMed Web of Science ®Google Scholar
• Griffin DE. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191, 117–134 (1995).
   PubMedGoogle Scholar
• Guillaume V, Contamin H, Loth P et al. Nipah virus: vaccination and passive protection studies in a hamster model. J. Virol. 78, 834–840 (2004).
   PubMed Web of Science ®Google Scholar
• Bossart KN, Crameri G, Dimitrov AS et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 79, 6690–6702 (2005).
   PubMed Web of Science ®Google Scholar
• Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3, 263–271 (2003).
   PubMedGoogle Scholar
• Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3(4 Suppl.), S75–S88 (2004).
   PubMed Web of Science ®Google Scholar
• Broder CC, Earl PL. Recombinant vaccinia viruses. Design, generation, and isolation. Mol. Biotechnol. 13, 223–245 (1999).
   PubMed Web of Science ®Google Scholar
• Murray PK, Eaton BT. Vaccines for bluetongue. Aust. Vet. J. 73, 207–210 (1996).
   PubMed Web of Science ®Google Scholar
• Pearson LD, Roy P. Genetically engineered multi-component virus-like particles as veterinary vaccines. Immunol. Cell Biol. 71(Pt 5), 381–389 (1993).
   PubMed Web of Science ®Google Scholar
• Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr. Opin. Oncol. 16, 485–491 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Dimitrov AS, Bossart KN et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891–899 (2006).
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin. Immunol. 93, 5–15 (1999).
   PubMed Web of Science ®Google Scholar
• Wright A, Shin SU, Morrison SL. Genetically engineered antibodies: progress and prospects. Crit. Rev. Immunol. 12, 125–168 (1992).
   PubMedGoogle Scholar
• Kang AS, Jones TM, Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc. Natl Acad. Sci. USA 88, 11120–11123 (1991).
   PubMedGoogle Scholar
• Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microbes Infect. 2, 701–708 (2000).
   PubMed Web of Science ®Google Scholar
• Rader C, Barbas CF III. Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol. 8, 503–508 (1997).
   PubMed Web of Science ®Google Scholar
• Hayden MS, Gilliland LK, Ledbetter JA. Antibody engineering. Curr. Opin. Immunol. 9, 201–212 (1997).
   PubMed Web of Science ®Google Scholar
• Hudson PJ, Souriau C. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 1, 845–855 (2001).
   PubMed Web of Science ®Google Scholar
• Weissenhorn W, Dessen A, Calder LJ et al. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 16, 3–9 (1999).
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 93, 681–684 (1998).
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 95, 871–874 (1998).
   PubMed Web of Science ®Google Scholar
• Singh M, Berger B, Kim PS. LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteins. J. Mol. Biol. 290, 1031–1041 (1999).
   PubMedGoogle Scholar
• Hughson FM. Enveloped viruses: a common mode of membrane fusion? Curr. Biol. 7, R565–R569 (1997).
   Web of Science ®Google Scholar
• Xu Y, Gao S, Cole DK et al. Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem. Biophys. Res. Commun. 315, 664–670 (2004).
   PubMedGoogle Scholar
• Bossart KN, Wang LF, Eaton BT, Broder CC. Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. Virology 290, 121–135 (2001).
   PubMed Web of Science ®Google Scholar
• Chambers P, Pringle CR, Easton AJ. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71, 3075–3080 (1990).
   PubMed Web of Science ®Google Scholar
• Earp LJ, Delos SE, Park HE, White JM. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 285, 25–66 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss CD. HIV-1 gp41: mediator of fusion and target for inhibition. AIDS Rev. 5, 214–221 (2003).
   PubMedGoogle Scholar
• Kilby JM, Hopkins S, Venetta TM et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302–1307 (1998).
   PubMed Web of Science ®Google Scholar
• Kilby JM, Lalezari JP, Eron JJ et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses18,685–693 (2002).
   PubMed Web of Science ®Google Scholar
• Xu Y, Lou Z, Liu Y et al. Crystallization and preliminary crystallographic analysis of the fusion core from two new zoonotic paramyxoviruses, Nipah virus and Hendra virus. Acta Crystallogr. D Biol. Crystallogr. 60, 1161–1164 (2004).
   PubMedGoogle Scholar
• Lambert DM, Barney S, Lambert AL et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl Acad. Sci. USA 93, 2186–2191 (1996).
   PubMed Web of Science ®Google Scholar
• Joshi SB, Dutch RE, Lamb RA. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 248, 20–34 (1998).
   PubMed Web of Science ®Google Scholar
• Wild TF, Buckland R. Inhibition of measles virus infection and fusion with peptides corresponding to the leucine zipper region of the fusion protein. J. Gen. Virol. 78, 107–111 (1997).
   PubMedGoogle Scholar
• Young JK, Li D, Abramowitz MC, Morrison TG. Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. J. Virol. 73, 5945–5956 (1999).
   PubMed Web of Science ®Google Scholar
• Young JK, Hicks RP, Wright GE, Morrison TG. Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling. Virology 238, 291–304 (1997).
   PubMed Web of Science ®Google Scholar
• Rapaport D, Ovadia M, Shai Y. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J. 14, 5524–5531 (1995).
   PubMed Web of Science ®Google Scholar
• Bossart KN, Wang LF, Flora MN et al. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J. Virol. 76, 11186–11198 (2002).
   PubMed Web of Science ®Google Scholar
• Bossart KN, Broder CC. Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol. Biol. 269, 309–332 (2004).
   PubMedGoogle Scholar
• Bossart KN, Mungall BA, Crameri G et al. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol. J. 2, 57 (2005).
   PubMedGoogle Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001).
   PubMed Web of Science ®Google Scholar
• Delgado C, Pedley RB, Herraez A et al. Enhanced tumour specificity of an anticarcinoembrionic antigen Fab’ fragment by poly(ethylene glycol) (PEG) modification. Br. J. Cancer 73, 175–182 (1996).
   PubMed Web of Science ®Google Scholar
• Delgado C, Malik F, Selisko B, Fisher D, Francis GE. Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems. J. Biochem. Biophys. Methods 29, 237–250 (1994).
   PubMedGoogle Scholar
• Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261–1277 (2003).
   PubMed Web of Science ®Google Scholar
• Pager CT, Dutch RE. Cathepsin L is involved in proteolytic processing of the hendra virus fusion protein. J. Virol. 79, 12714–12720 (2005).
   PubMedGoogle Scholar
• Sever N, Filipic M, Brzin J, Lah TT. Effect of cysteine proteinase inhibitors on murine B16 melanoma cell invasion in vitro. Biol. Chem. 383, 839–842 (2002).
   PubMedGoogle Scholar
• Yasuma T, Oi S, Choh N et al. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J. Med. Chem. 41, 4301–4308 (1998).
   PubMed Web of Science ®Google Scholar
• Diederich S, Moll M, Klenk HD, Maisner A. The Nipah virus fusion protein is cleaved within the endosomal compartment. J. Biol. Chem. 280, 29899–29903 (2005).
   PubMedGoogle Scholar
• Masood R, Xia G, Smith DL et al. Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus Type 8: phenotype switch from venous to arterial endothelium. Blood 105, 1310–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Martiny-Baron G, Korff T, Schaffner F et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6, 248–257 (2004).
   PubMed Web of Science ®Google Scholar
• Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 15, 419–433 (2004).
   PubMed Web of Science ®Google Scholar
• Crumpacker C. Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, PA, USA, 393–433 (2001).
   Google Scholar
• Sidwell RW, Huffman JH, Khare GP et al. Broad spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177, 705–706 (1972).
   PubMed Web of Science ®Google Scholar
• Snell NJ. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother.2,1317–1324 (2001).
   PubMedGoogle Scholar
• Heathcote J, Main J. Treatment of hepatitis C. J. Viral. Hepat. 12, 223–235 (2005).
   PubMed Web of Science ®Google Scholar
• Chong HT, Kamarulzaman A, Tan CT et al. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neurol. 49, 810–813 (2001).
   PubMed Web of Science ®Google Scholar
• Snell NJ. Ribavirin therapy for Nipah virus infection. J. Virol. 78, 10211 (2004).
   PubMedGoogle Scholar
• Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809 (2001).
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2, 675–687 (2002).
   PubMed Web of Science ®Google Scholar
• Poole E, He B, Lamb RA, Randall RE, Goodbourn S. The V proteins of simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 303, 33–46 (2002).
   PubMedGoogle Scholar
• He B, Paterson RG, Stock N et al. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303, 15–32 (2002).
   PubMedGoogle Scholar
• Gotoh B, Komatsu T, Takeuchi K, Yokoo J. Paramyxovirus strategies for evading the interferon response. Rev. Med. Virol. 12, 337–357 (2002).
   PubMed Web of Science ®Google Scholar
• Didcock L, Young DF, Goodbourn S, Randall RE. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol. 73, 9928–9933 (1999).
   PubMedGoogle Scholar
• Kubota T, Yokosawa N, Yokota S et al. Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J. Virol. 79, 4451–4459 (2005).
   PubMedGoogle Scholar
• Parisien JP, Lau JF, Rodriguez JJ et al. The V protein of human parainfluenza virus 2 antagonizes Type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 283, 230–239 (2001).
   PubMedGoogle Scholar
• Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4, 23–35 (2006).
   PubMed Web of Science ®Google Scholar
• Wang LF, Michalski WP, Yu M et al. A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals. J. Virol. 72, 1482–1490 (1998).
   PubMed Web of Science ®Google Scholar
• Harcourt BH, Tamin A, Ksiazek TG et al. Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 271, 334–349 (2000).
   PubMed Web of Science ®Google Scholar
• Rodriguez JJ, Horvath CM. Host evasion by emerging paramyxoviruses: Hendra virus and Nipah virus V proteins inhibit interferon signaling. Viral Immunol. 17, 210–219 (2004).
   PubMedGoogle Scholar
• Shaw ML, Garcia-Sastre A, Palese P, Basler CF. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J. Virol. 78, 5633–5641 (2004).
   PubMed Web of Science ®Google Scholar
• Park MS, Shaw ML, Munoz-Jordan J et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V W, and C proteins. J. Virol. 77, 1501–1511 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez JJ, Cruz CD, Horvath CM. Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. J. Virol. 78, 5358–5367 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J. Virol. 79, 6078–6088 (2005).
   PubMed Web of Science ®Google Scholar
• O’Sullivan JD, Allworth AM, Paterson DL et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 349, 93–95 (1997).
   PubMed Web of Science ®Google Scholar